Why it matters: Europe has developed a strong early-stage biotech investment ecosystem, but financing becomes more difficult as companies enter expensive clinical trials and approach commercialization. Sofinnova wants to help bridge that gap with larger investments and greater capacity to support companies over time.
“The gap comes later,” Kinam Hong, partner at Sofinnova Partners, told European Biotechnology. “Europe has outstanding science and a well-developed early-stage investment ecosystem, but capital becomes much thinner when companies move into larger clinical trials and need substantial investment to reach decisive milestones.”
By the numbers: Sofinnova Crossover II significantly exceeded its original fundraising target, although the firm did not disclose that target.
- Its predecessor, Crossover I, closed at €445 million in March 2021.
- In November 2025, Sofinnova also closed its €650 million Capital XI fund, dedicated to early-stage healthcare investments.
- Together, the two latest funds represent €1.375 billion raised across Sofinnova’s early- and late-stage strategies in about a year.
Zoom in: Crossover II will invest in private and publicly traded companies, primarily in Europe, with selective investments in the U.S. and other markets. Despite the larger fund size, Sofinnova is keeping its portfolio concentrated, allowing it to reserve more capital for follow-on investments.
“As companies move through clinical development, the rounds get larger and the available capital becomes much thinner,” Hong explained. “Crossover I also taught us that companies often need support for longer than planned, particularly when public markets are closed.”
He pointed to Abivax as an example. Sofinnova continued financing the French biotech through difficult market conditions until it reached its Phase 3 clinical data. “The objective is not merely to fund one clinical milestone. It is to give companies a credible financing path through several stages of development,” Hong said.
Sofinnova declined to specify its target initial investment size or the proportion of the fund reserved for follow-on financing.
Who’s investing? Crossover II attracted sovereign funds, insurers, public institutions and other institutional investors. According to Hong, the fund secured a high rate of returning investors from Crossover I while bringing in new limited partners (LPs). “Our investor base is broader and more international than for Crossover I,” he said.
European institutions remain central to the fund, including the European Tech Champions Initiative (ETCI), managed by the European Investment Fund. The EU-backed initiative was created to increase the availability of large investment tickets for European scale-ups by investing in venture capital and growth funds.
However, Sofinnova also attracted investors from outside Europe. “Global investors recognize both the quality of European life sciences innovation and the need for specialist capital to support companies through later-stage development,” Hong said. “But Europe still lacks enough large, specialist pools of capital for this stage. That is why initiatives like ETCI matter.”
The track record: Sofinnova says the 16 companies backed by Crossover I subsequently raised another €3.4 billion. The portfolio includes several high-profile exits, including Amolyt Pharma’s acquisition by AstraZeneca for up to $1.05 billion, Calliditas Therapeutics’ sale to Asahi Kasei and LimFlow’s acquisition by Inari Medical. Abivax, which trades on Nasdaq, also reached a major Phase 3 milestone with Sofinnova’s continued backing.
“The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets,” said Antoine Papiernik, chairman and managing partner of Sofinnova Partners.
The big picture: Sofinnova’s fundraising success comes as many smaller and emerging VC managers face difficulties securing commitments from institutional investors, raising questions about whether capital is becoming increasingly concentrated among established firms.
“Investors are being selective, and they are backing managers who can show results,” Hong said. But he argued that this concentration should not come at the expense of the broader investment ecosystem. “A healthy ecosystem needs capital at every stage. Strong early-stage investors create the companies that later-stage funds like ours can help grow,” he said.
For Hong, increasing the availability of growth capital also benefits early-stage investors by giving their portfolio companies more financing options as they mature.
Already investing: Crossover II has backed three European companies: Denmark-born Hemab Therapeutics, which develops treatments for serious bleeding and clotting disorders and listed on Nasdaq this year; the U.K.’s CellCentric, which is developing an oral treatment for multiple myeloma and other cancers; and Ireland’s Neurent Medical, which develops a minimally invasive treatment for chronic rhinitis.
According to Hong, the companies reflect Sofinnova’s focus on medical innovation backed by early clinical evidence, with the potential to address significant unmet needs.
Bottom line: With €725 million available, Sofinnova has increased its capacity to finance European life sciences companies through expensive clinical development programs and difficult market conditions. Its latest fundraising success also highlights a broader challenge: ensuring the European investment ecosystem has enough capital at every stage, not just among its largest fund managers.
Sign up for our newsletter!
